Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing